These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 28328761)
21. [Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis]. Sabanov AV; Luneva AV; Matveev NV Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(5):65-9. PubMed ID: 24988963 [TBL] [Abstract][Full Text] [Related]
22. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists. Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E; J Clin Neurosci; 2014 Nov; 21(11):1847-56. PubMed ID: 24986155 [TBL] [Abstract][Full Text] [Related]
23. Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy. Freedman MS Eur J Neurol; 2014 Mar; 21(3):377-87, e18-20. PubMed ID: 24237582 [TBL] [Abstract][Full Text] [Related]
24. Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates. Dubey D; Kieseier BC; Hartung HP; Hemmer B; Miller-Little WA; Stuve O Expert Rev Clin Immunol; 2015 Jan; 11(1):93-108. PubMed ID: 25495182 [TBL] [Abstract][Full Text] [Related]
25. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581 [TBL] [Abstract][Full Text] [Related]
26. Alemtuzumab treatment of multiple sclerosis. Coles AJ Semin Neurol; 2013 Feb; 33(1):66-73. PubMed ID: 23709214 [TBL] [Abstract][Full Text] [Related]
27. Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Cree BAC; Mares J; Hartung HP Curr Opin Neurol; 2019 Jun; 32(3):365-377. PubMed ID: 30985372 [TBL] [Abstract][Full Text] [Related]
28. [Monoclonal antibodies for the treatment of multiple sclerosis]. Sánchez-Seco VG; Casanova Peño I; Arroyo González R Med Clin (Barc); 2014 Dec; 143 Suppl 3():30-4. PubMed ID: 25732947 [TBL] [Abstract][Full Text] [Related]
29. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Wingerchuk DM; Carter JL Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135 [TBL] [Abstract][Full Text] [Related]
30. Treatment of children and adolescents with multiple sclerosis. Banwell B Expert Rev Neurother; 2005 May; 5(3):391-401. PubMed ID: 15938672 [TBL] [Abstract][Full Text] [Related]
31. Antidrug Antibodies: B Cell Immunity Against Therapy. Fogdell-Hahn A Scand J Immunol; 2015 Sep; 82(3):184-90. PubMed ID: 26098690 [TBL] [Abstract][Full Text] [Related]